BMJ
- IACOBUCCI G
Childhood vaccinations: Falling rates in England are "national disgrace," say
MPs.
BMJ. 2026;392:s139.
- TANNE JH
US medical groups file lawsuit to stop RFK Jr's vaccine changes.
BMJ. 2026;392:s145.
- MAHASE E
UK is better protected than US against vaccine politicisation-but is not immune,
top adviser warns.
BMJ. 2026;392:s60.
Clin Infect Dis
- WINOKUR P, Diya O, Fitz-Patrick D, Dever M, et al
Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2
COVID-19 Vaccines in Adults 18?55 Years Old.
Clin Infect Dis. 2026 Jan 21:ciag026. doi: 10.1093.
J Infect Dis
- ZHANG X
How "Enhanced" Are Enhanced Influenza Vaccines for Neuraminidase? Antigen Content
and Baseline Immunity Revisited.
J Infect Dis. 2026 Jan 23:jiag042. doi: 10.1093.
- CHATURVEDI AK, Haber G, Graubard BI, Cheung LC, et al
Risk-based prophylactic HPV vaccination of heterosexual US men aged 27 to 45
years for prevention of oropharyngeal cancer.
J Infect Dis. 2026 Jan 20:jiag038. doi: 10.1093.
- SONG EM, An HM, Kim SE, Shim KN, et al
Coronavirus Disease 2019 Risk in Patients With Autoimmune Diseases Using
Biologics or Small Molecules: A Population-Based Cohort Study.
J Infect Dis. 2026;233:137-147.
- BIDARI S, Yuan H, Yang W
Assessing the Transmissibility and Outbreak Risk of Measles in the United States,
2024-2030.
J Infect Dis. 2026;233:132-136.
J Pediatr
- MCCLURE DL, Hanson KE, Sundaram ME, Kieke BA, et al
Incident Epilepsy and Vaccination Status or Vaccine Aluminum Exposure in Children
Under Age 4.
J Pediatr. 2026 Jan 19:115004. doi: 10.1016/j.jpeds.2026.115004.
Lancet
- POLLARD AJ, Plotkin S
A risk to child health: confusion and concern over changes to US vaccine policy.
Lancet. 2026 Jan 20:S0140-6736(26)00090-5. doi: 10.1016/S0140-6736(26)00090.
Nat Med
- KIM K, Title B, Kipnis J
Placebo effect influences vaccine responses.
Nat Med. 2026 Jan 19. doi: 10.1038/s41591-025-04168.
- LUBIANIKER N, Koren T, Djerasi M, Sirotkin M, et al
Upregulation of reward mesolimbic activity and immune response to vaccination: a
randomized controlled trial.
Nat Med. 2026 Jan 19. doi: 10.1038/s41591-025-04140.
- WONG GL, Yuen MF, Lin B, Douglas MW, et al
Elebsiran and PEG-IFNalpha for chronic hepatitis B infection: a partially randomized,
open-label, phase 2 trial.
Nat Med. 2026;32:151-159.
PLoS Med
- MONOI A, Endo A, Procter SR, Leuba SI, et al
The benefits and risks of maternal RSV vaccination on mortality in South Africa:
A modeling study.
PLoS Med. 2026;23:e1004625.
PLoS One
- HOU Y, Chen H, Jiang Y, Huang H, et al
Shifting epidemiological patterns and strain replacement of hand, foot, and mouth
disease in southern China, 2009-2022: A longitudinal study.
PLoS One. 2026;21:e0341302.
- SULIS G, Maredia N, Wolfson C, Basta NE, et al
Changes in pneumococcal vaccine coverage in the Canadian Longitudinal Study on
Aging (CLSA): An analysis based on the 2018-2021 follow-up 2 survey.
PLoS One. 2026;21:e0338213.
Proc Natl Acad Sci U S A
- GERVAIS A, Bastard P, Zhang Q, Jaffar-Bandjee MC, et al
Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine
encephalitis.
Proc Natl Acad Sci U S A. 2026;123:e2532212123.
- TE N, Chin AWH, Gu H, Zhirong Jia J, et al
Broad beta-CoV immunity and transmission blockade by a single-dose
live-attenuated vaccine with atypical codon usage.
Proc Natl Acad Sci U S A. 2026;123:e2518645123.
Vaccine
- WOO EJ
Adjuvanted recombinant zoster vaccine and live attenuated zoster vaccine are
vastly different.
Vaccine. 2026 Jan 23:128272. doi: 10.1016/j.vaccine.2026.128272.
- STUART R, Theopold N, Miall N, Kobayashi E, et al
The role of HPV single-dose vaccination in expanding access in GAVI-supported
countries during a period of supply constraints.
Vaccine. 2026;75:128187.
- ADAM A, Lee C, Jones MC, Harrington BR, et al
VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine.
Vaccine. 2026;75:128255.
- LI J, Kyaw PE, Tan C, Wen K, et al
Development of duck hepatitis A virus type 1 attenuated vaccine E23-SP80 and its
protective efficacy evaluation against DHAV-1 infection in ducks.
Vaccine. 2026;75:128258.
- LANGLEY JM, Sadarangani M, Ockenhouse C, Barreto L, et al
Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in
pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled
clinical trials.
Vaccine. 2026;75:128236.
- VATTOTH AL, Hayney MS, Forati AM, Warren B, et al
Immunogenicity and safety of a recombinant spike protein COVID vaccine in
patients with inflammatory bowel disease and transplant recipient.
Vaccine. 2026;75:128208.
- JEONG O, Choi W, Ahn H, Lee S, et al
Bromelain-cleaved hemagglutinin production from cell culture-derived influenza
viruses enhances vaccine potency quantification by single radial immunodiffusion
assay.
Vaccine. 2026;75:128235.
- YESENIA RODRIGUEZ-TANTA L, Delgado-Escalante R, Del Pilar Solis-Yucra T, Rojas EC, et al
Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 vaccine
in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance
Center.
Vaccine. 2026;75:128227.
- YIGIT I, Stoner MCD, Muessig KE, Hightow-Weidman LB, et al
Pathways to COVID-19 vaccine initiation: The roles of medical mistrust,
conspiracy beliefs, hesitancy, and confidence among black young adults.
Vaccine. 2026;75:128253.
- SHI L, Chen J, Li H, Yan X, et al
Safety, immunogenicity, and lot consistency of a 13-valent pneumococcal conjugate
vaccine in Chinese children aged 2-5 years: A phase III study.
Vaccine. 2026;75:128244.
- NIKHAB A, Patel T, Rooney G, Wasti S, et al
Assessing the potential impact of the 20-valent (PCV20) and an adult 21-valent
(aPCV21) pneumococcal conjugate vaccine on invasive pneumococcal disease in
England.
Vaccine. 2026;75:128246.
- HANDY AB, Ren B, Seidman LC, Granger SW, et al
Inflammatory mechanisms of menstrual cycle changes following COVID-19 vaccination
in adolescents.
Vaccine. 2026;75:128226.
- SIM SY, Silal S, Hutubessy RC, Bar-Zeev N, et al
Advancing the use of vaccine impact modeling for immunization decisions in low-
and middle-income countries.
Vaccine. 2026;75:128239.
- CHELLAPPAN G, Seal F, Balasundaram WU, Zhao Y, et al
Preclinical immunogenicity studies of Haemophilus influenzae type a
glycoconjugate vaccine.
Vaccine. 2026;75:128242.
- SIGAUQUE B, Vilanculos L, Chauque A, Moiane B, et al
Effectiveness of 10-valent pneumococcal conjugate vaccine against radiologically
confirmed pneumonia and invasive pneumococcal disease among young children in
Mozambique.
Vaccine. 2026;75:128237.
- WU B, Cheng T, Zhang Y, Kezhong A, et al
Adult and maternal pertussis vaccination in China: intention, preferences, and
pricing implications from a discrete choice experiment.
Vaccine. 2026;75:128243.
- CHANGALUCHA J, Ferguson E, Luka MM, Lushasi K, et al
Comparative effectiveness and cost-effectiveness of policies for provisioning
rabies post-exposure vaccines.
Vaccine. 2026;74:128178.
- AYABINA D, Stoecker C, Cho BH, Prasad N, et al
Public health impact and cost-effectiveness of 20-valent pneumococcal conjugate
vaccine use among children in the United States.
Vaccine. 2026;74:128212.
- KLING K, Falman A, Branke L, Ramharter M, et al
Vaccination against chikungunya - a systematic review on the immunogenicity,
tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the
virus like particle (VLP) vaccine Vimkunya.
Vaccine. 2026;75:128251.
- SHUAI W, Sun Q, Li J, Shen W, et al
Needle-free intradermal delivery of a recombinant PRRSV-vectored CSFV E2 vaccine
enhances humoral immunity and growth performance in piglets.
Vaccine. 2026;75:128247.
- FAIJUE DD, Bouaddi O, Mackey K, Deal A, et al
Strategies, interventions, and uptake of catch-up vaccination among adolescent
and adult migrants, refugees, and internally displaced persons (IDPs) in low- and
middle-income countries (LMICs): A systematic review.
Vaccine. 2026;75:128249.
- FLOROS L, Johnson KD, Tsoumani E
Serotype-specific incidence and comparative vaccine coverage of invasive
pneumococcal disease among adults >/=65 years of age in European countries from
2011 to 2023.
Vaccine. 2026;75:128181.
- LISTER H, Farquharson K, Seale H, Smith LE, et al
Erratum to "A systematic review of the impact of vaccine reactogenicity on
willingness to accept influenza vaccination in adults" [Vaccine 74 (2026)
128195].
Vaccine. 2026;75:128252.
- MVUNDURA M, Slavkovsky R, Dagnew B, Hunduma A, et al
Evaluating the delivery costs and operational context of a single-dose human
papillomavirus (HPV) vaccine regimen administered to a multi-age cohort of
adolescent girls in Ethiopia.
Vaccine. 2026;75:128248.
- BARBEY FA, Otth M, Kroiss S, Drozdov D, et al
Adherence to national vaccination guidelines among pediatric cancer patients: a
retrospective study from two tertiary care centers in Switzerland.
Vaccine. 2026;75:128265.
- TEMBO G, Hoving D, de Kroon AC, Chimgoneko L, et al
13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but
not serotype 3 capsule-specific IgG antibodies in young Malawian adults.
Vaccine. 2026;75:128269.
- CONTARINO F, Fiorilla C, Bella F, Orsi A, et al
Exploring regional variations in the provision of influenza vaccination in Italy.
Vaccine. 2026;75:128266.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016